Abstract:Objective: To analyze the clinical characteristics and prognosis of patients with myelodysplastic syndrome (MDS) with a bone marrow nucleated erythroid cell proportion of greater than or equal to 50% (MDS-E) . Methods: The clinical characteristics and prognostic factors of patients with MDS-E were retrospectively analyzed by collecting the case data of 1 436 newly treated patients with MDS diagnosed in the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences from May 2014 to June 2023. Results: A total of 1 436 newly diagnosed patients with complete data were included in the study, of which 337 (23.5%) patients with MDS-E had a younger age of onset and lower neutrophil and platelet counts compared with those in patients with an erythroid cell proportion of less than 50% (MDS-NE) (all P<0.05). The proportion of MDS cases with ring sideroblasts (MDS-RS) was higher in the MDS-E group than in the MDS-NE group, and multi-hit TP53 mutations were more enriched in the MDS-E group than in the MDS-NE group (all P<0.05). Among patients with MDS-RS, the frequency of complex karyotypes and the TP53 mutation rate were significantly lower in the MDS-E group than in the MDS-NE group (0 vs 11.9%, P=0.048 and 2.4% vs 15.1%, P=0.053, respectively). Among patients with TP53 mutations, the frequencies of complex karyotypes and multi-hit TP53 mutations were significantly higher in the MDS-E group than in the MDS-NE group (87.5% vs 64.6%, P=0.003 and 84.0% vs 54.2%, P<0.001, respectively). Survival analysis of patients with MDS-RS found that the overall survival (OS) in the MDS-E group was better than that in the MDS-NE group [not reached vs 63 (95% CI 53.3-72.7) months, P=0.029]. Among patients with TP53 mutations and excess blasts, the OS in the MDS-E group was worse than that in the MDS-NE group [6 (95% CI 2.2-9.8) months vs 12 (95% CI 8.9-15.1) months, P=0.022]. Multivariate analysis showed that age of ≥65 years (HR=2.47, 95% CI 1.43-4.26, P=0.001), mean corpuscular volume (MCV) of ≤100 fl (HR=2.62, 95% CI 1.54-4.47, P<0.001), and TP53 mutation (HR=2.31, 95% CI 1.29-4.12, P=0.005) were poor prognostic factors independent of the Revised International Prognostic Scoring System (IPSS-R) prognosis stratification in patients with MDS-E. Conclusion: Among patients with MDS-RS, MDS-E was strongly associated with a lower proportion of complex karyotypes and TP53 mutations, and the OS in the MDS-E group was longer than that in the MDS-NE group. Among patients with TP53 mutations, MDS-E was strongly associated with complex karyotypes and multi-hit TP53 mutations, and among TP53-mutated patients with excess blasts, the OS in the MDS-E group was shorter than that in the MDS-NE group. Age of ≥65 years, MCV of ≤100 fl, and TP53 mutation were independent adverse prognostic factors affecting OS in patients with MDS-E.

Low RPS14 gene expression is accompanied by p53-independent apoptosis in MDS patients with 5q- aberrations

Low Expression of RPS14 Accompanied with P53-Independent Over-Apoptosis in Myelodysplastic Syndromes Patients with 5Q- Aberration

Low RPS14 Expression in MDS Without 5q - Aberration Confers Higher Apoptosis Rate of Nucleated Erythrocytes and Predicts Prolonged Survival and Possible Response to Lenalidomide in Lower Risk Non-5Q- Patients.

Research status of p53 in the pathogenesis of 5q-syndrome

Clinical Significance of Cytogenetic and Molecular Genetic Abnormalities in 634 Chinese Patients with Myelodysplastic Syndromes

Low RPS14 Expression in MDS without 5q- Aberration Is Associated with Increased Apoptosis of Erythrocytes and Predicts Prolonged Survival and Possible Response to Lenalidomide in Lower-Risk Patients

Study on Methylation of P15ink4b Gene and Its Mechanisms in Patients with Myelodysplastic Syndrome and Leukemia.

TP53 Mutations Are Associated with Very Complex Karyotype and Suggest Poor Prognosis in Newly Diagnosed Myelodysplastic Syndrome Patients with Monosomal Karyotype.

Clinical analysis on 15 acute myeloid leukemia patients with 11p15 abnormalities

Over-expression of RPL23 in myelodysplastic syndromes is associated with apoptosis resistance of CD34 + cells and predicts poor prognosis and distinct response to CHG chemotherapy or decitabine

Ribosomal Protein L23 Negatively Regulates Cell Apoptosis Via Its Suppression of Miz1 and Activation C-Myc in Higher-Risk Myelodysplastic Syndromes

Ezh2-Mediated Activation of Serine Biosynthetic Pathway is Critical for Resistance of Clonal Cells to Stress-Related Apoptosis in Low-Grade Myelodysplastic Syndrome

[Clinical characteristics and prognosis of patients with myelodysplastic syndrome with a bone marrow nucleated erythroid cell proportion of greater than or equal to 50]

Investigation of the molecular causes underlying physical abnormalities in Diamond-Blackfan anemia patients with RPL5 haploinsufficiency

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes

[Abnormal Expression of PDCD5 in the Bone Marrow Cells of Adult Acute Myeloid Leukemia].

Reduced Response to Stromal Cell-Derived Factor-1(SDF-1) May Lead to Low Expression of P57kip2 in the Bone Marrow of Patients with De Novo Myelodysplastic Syndromes (MDS)

Ribosomal Protein L23 Negatively Regulates Cellular Apoptosis Via the RPL23/Miz-1/C-Myc Circuit in Higher-Risk Myelodysplastic Syndrome

[Study of Aberrant P73 Promoter Methylation in Patients with Myelodysplastic Syndrome].

Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: Differential diagnosis between refractory anemia and aplastic anemia

Probe into the Apoptosis Rate of Bone Marrow Mononuclear Cells in Myelodysplastic Syndromes